Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of cardiac arrhythmia in pediatric patients with Left Ventricular Assist Device (L-VAD).

European review for medical and pharmacological sciences·2024

Same author

Dynamic thiol/disulphide homeostasis and ischemic modified albumin levels in isolated oligohydramnios.

Taiwanese journal of obstetrics & gynecology·2021

Same author

Lycopene has a protective effect on septic shock‑induced cardiac injury in rats.

Bratislavske lekarske listy·2019

Same author

Autoimmune haemolytic anaemia and thrombocytopaenia in a single-centre cohort of patients with systemic lupus erythematosus from Turkey: clinical associations and effect on disease damage and survival.

Lupus·2019

Same author

The effect of different irrigation protocols on elastic modulus of dentine and biomechanics of single-rooted premolar tooth: A nano-indentation and finite element analysis study.

Nigerian journal of clinical practice·2019

Same author

Test-retest reliability of subjective supra-threshold scaling of multiple pressure-pain sensations among healthy individuals: a study using hydraulic pressure algometry.

Somatosensory & motor research·2018

Search research articles

Related Experiment Video

Updated: May 20, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Changing face of heart failure surgery.

T Yagdi¹, E Oguz, C Engin

¹Department of Cardiovascular Surgery, Ege University Medical Faculty, Izmir, Turkey. tahir.yagdi@ege.edu.tr

Transplantation Proceedings

|July 31, 2012

Summary

Vascular assist devices (VADs) significantly reduce mortality for heart failure patients awaiting transplants. VADs improve survival rates, allowing more patients to receive life-saving heart transplants.

More Related Videos

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Related Experiment Videos

Last Updated: May 20, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Area of Science:

Cardiology
Cardiovascular Surgery
Medical Devices

Background:

Heart failure is a leading cause of death, with donor organ scarcity limiting heart transplantation success.
The waiting period for heart transplantation poses a significant mortality risk for end-stage heart failure patients.

Purpose of the Study:

To evaluate the impact of vascular assist devices (VADs) on patient outcomes in end-stage heart failure surgery.
To assess the role of VADs in reducing mortality among heart transplant candidates.

Main Methods:

Retrospective analysis of 159 heart failure patients (1998-2011), with 67 receiving VAD implantation after April 2007.
Comparison of outcomes for patients undergoing heart transplantation with and without prior VAD support.

Main Results:

VAD implantation showed no intraoperative deaths among 67 patients, with a mean support time of 214 days.
Overall survival to transplantation or weaning was 77.6%, with 90% survival achieved using continuous flow pumps.
Post-VAD introduction, nearly 80% of donor hearts were utilized for patients on mechanical circulatory support.

Conclusions:

Vascular assist devices have radically improved outcomes in heart failure surgery since 2007.
VADs significantly reduce patient loss on the waiting list for heart transplantation.
Mechanical circulatory support via VADs enhances the utilization of donor organs for critically ill patients.